According to FutureWise analysis the market for Lacrimal Duct Stent Tube is expected to register a CAGR of 5.42% from 2023-2031.
Rising patient population, growing demand for minimally invasive treatments are some of the factors responsible for the growth of the market. Dacryostenosis or nasolacrimal duct obstruction is the most prevalent lacrimal system disorder. As per the article ‘Nasolacrimal Duct Obstruction’ published in 2020, over 15% of infant patients possessing with some symptoms. The rate of spontaneous NLDO resolution with over 65% of affected children getting symptom-free within 3 months and over 85% recovering within a year. On the other hand, new-born babies at a high risk for this condition which include ectrodactyly-ectodermal dysplasia-cleft lip syndrome, trisomy 21, coloboma, heart anomaly, choanal atresia and retardation syndrome, branchiooculofacial syndrome, Goldenhar syndrome. Therefore, the rising incidence of such conditions shall propel the lacrimal duct stent tube market growth.
Lacrimal intubation has been a very prevalent surgery for congenital NLDO over the past few years. This procedure does not respond to failed probing or conservative medical treatments. Furthermore, there are other health conditions related to lacrimal duct obstruction like for instance, dacryocystitis is an inflammation caused in the nasolacrimal sac is generally followed by nasolacrimal duct blockage. Owing to the high incidence of such conditions shall boost the proliferation of the market.